ReviewTherapeutic advances in medical oncology2020
Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?
Review in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07173374 (Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A Single-Arm Phase I Safety and Feasibility Study
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Impact of Depression on Mortality in Patients with Pancreatic Cancer: A Systematic Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021Trial
- Suicide Risk and Associated Factors in Patients with Pancreatic Cancer: A Systematic Review.Diseases (Basel, Switzerland) · 2026Review
- Current practices and challenges in the management of nonmetastatic pancreatic adenocarcinoma: results of an EORTC survey.ESMO gastrointestinal oncology · 2026Article
- Octogenarians Undergoing Pancreaticoduodenectomy versus Definitive Radiotherapy for Locoregional Therapy of Pancreatic Ductal Adenocarcinoma: A Nationwide Analysis.Annals of surgical oncology · 2026Article
- Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-dose stereotactic body radiotherapy.British journal of cancer · 2026Article
- Evaluation of loco-regional recurrences using deformable image registration after isotoxic high dose stereotactic body radiotherapy in localised pancreatic cancer.Clinical and translational radiation oncology · 2026Article
- BE-43547AActa pharmacologica Sinica · 2025Article
- Raman spectroscopy based diagnosis of pancreatic ductal adenocarcinoma.Scientific reports · 2025Article
- Combined physical and biological contributions to radiotherapy enhancement by Lu-based nanoscintillators in pancreatic cancer models.Nanotheranostics · 2025Article
- Article
- Review
- Neoadjuvant chemotherapy may be the best neoadjuvant therapy modality for non-metastatic pancreatic cancer: a population based study.Frontiers in oncology · 2024Article
- Chinese herbal injections in combination with radiotherapy for advanced pancreatic cancer: A systematic review and network meta-analysis.Integrative medicine research · 2023Review
- Review
- Review
- The current understanding of the immune landscape relative to radiotherapy across tumor types.Frontiers in immunology · 2023Review
- Article
- Deterioration of pancreatic exocrine function in carbon ion radiotherapy for pancreatic cancer.Clinical and translational radiation oncology · 2021Article
- What Should Guide the Performance of Venous Resection During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma with Venous Contact?Annals of surgical oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive solid tumours with an estimated 5-year overall survival rate of 7% for all stages combined. In this highly resistant disease that is located in the vicinity of many radiosensitive organs, the role of radiotherapy (RT) and indications for its use in this setting have been debated for a long time and are still under investigation. Although a survival benefit has yet to be clearly demonstrated for RT, it is the only technique, other than surgery, that has been demonstrated to lead to local control improvement. The adjuvant approach is now strongly challenged by neoadjuvant treatments that could spare patients with rapidly progressive systemic disease from unnecessary surgery and may increase free margin (R0) resection rates for those eligible for surgery. Recently developed dose-escalated RT treatments, designed either to maintain full-dose chemotherapy or to deliver a high biologically effective dose, particularly to areas of contact between the tumour and blood vessels, such as hypofractionated ablative RT (HFA-RT) or stereotactic body RT (SBRT), are progressively changing the treatment landscape. These modern strategies are currently being tested in prospective clinical trials with encouraging preliminary results, paving the way for more effective treatment combinations using novel targeted therapies. This review summarizes the current literature regarding the use of RT for the treatment of primary PDAC, describes the limitations of conventional RT, and discusses the emerging role of dose-escalated RT and heavy-particle RT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.